Evaluation of Early Identification of Cognitive Side Effects of Immunotherapy
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorMasonic Cancer Center, University of Minnesota
About this trial
This clinical trial evaluates the use of a tool kit, Stress, Affect, Language and Speech Analysis (SALSA), for early identification of cognitive side effects of immunotherapy compared to the standard of care assessment.
Eligibility criteria
Qualifiers
* ≥ 18 years of age at initiation of therapy
Planning to undergo inpatient CAR-T therapy for primary malignancy
Fluent in English (written or spoken)
Disqualifiers
* Subjects with speech or hearing impediment that would make them unable to be assessed with SALSA
Subjects with diagnosed cognitive impairment prior to CAR-T therapy
Unwilling or unable to sign voluntary written consent
Trial design
Treatments tested in this trial
- Non-Interventional Study
Treatment groups
38 Participants
are divided into 1 treatment groupSponsors and collaborators
Masonic Cancer Center, University of Minnesota
Lead sponsor
National Cancer Institute (NCI)
Collaborator
Source ClinicalTrials.gov